In 2021, we reported on the first 34 patients with recurrent angioedema due to C1INH deficiency, 30 patients with HAE-C1INH and 4 patients with AAE-C1INH, who were treated with lanadelumab at our Angioedema Center of Reference and Excellence (ACARE) (9, 10). This evidence concerns the gene SERPING1 and acquired angioedema.